NCT02727751View on ClinicalTrials.gov

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

PHASE3CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
DRUG

Tenapanor

Trial Locations (1)

Unknown

Ardelyx Clinical Site, Miami

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY

NCT02727751 - A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C | Biotech Hunter | Biotech Hunter